TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cirrhosis Readmission Telehealth Project

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age of at least 18~* Patients with known cirrhosis~* Current hospitalization for overt hepatic encephalopathy as categorized by West Haven encephalopathy score of 2 or more~* Current hospitalization found no precipitants triggering encephalopathy as determined by the primary team~* Encephalopathy resolved at time of enrollment~* Has a telephone~* Able to obtain medications~Exclusion Criteria:~* Altered mental status unrelated to cirrhosis~* Acute liver failure~* Expectation of liver transplant within 1 month after enrollment~* Chronic kidney disease with Cr \> 2 mg/dL~* Respiratory insufficiency:moderate to sever COPD on pulmonary function test~* Electrolyte imbalances not corrected at enrollment~* Sodium less than 125 mmol/L~* Calcium greater than 10mg/dL~* Potassium \< 2.5mmol/L~* Unable to give legal consent~* Deafness~* Infection, spontaneous bacterial peritonitis, gastrointestinal bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: NO_INTERVENTION): Patients recieve standard care. On discharge they receive an information packet about cirrhosis and hepatic encephalopathy. They will continue to follow with their doctor as usual.
- Phone calls (Type: EXPERIMENTAL): On discharge, patients will receive an information package about cirrhosis and hepatic encephalopathy. In addition to regular visits with the doctor, they will receive phone calls from one of our research providers who will be a nurse practitioner, doctor, or physician assistant. In the first 2 weeks after discharge, they will receive phone calls every other day. For the following 10 weeks, they will receive phone calls once a week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of a Nationwide Cognitive-Affective Remediation Training Intervention in Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* computer and broadband internet access~* 18 years of age~* Elevated anxiety and depression~* Native English speaker~Exclusion Criteria:

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Treatment Group (Type: EXPERIMENTAL): Participants randomized to receive remediation training intervention delivered online (60 days of online training)
- Control Group (Type: ACTIVE_COMPARATOR): Participants randomized to receive online gaming intervention (60 days of online play)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient receives lorlatinib through Pfizer's expanded access program for treatment of ALK+ neuroblastoma.~* HCP documentation of at least one tumor assessment of response after patient has had at least one dose of lorlatinib~* Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.~Exclusion Criteria:~* Any patient who does not meet any of the inclusion criteria defined in the previous section.

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pediatric Neuroblastoma Patients Treated with Lorlatinib (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Paclitaxel-Coated Balloons Against Drug-Eluting Bioresorbable Scaffolds for Elective PCI Using OCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* written consent~* indication for elective PCI of a de novo coronary stenosis in a native vessel~* coronary multivessel disease with clinically proven indication for repeating coronary angiography at 6-9 months (staged PCI strategy)~Exclusion Criteria:~* pregnancy, lactation, women of childbearing age w/o reliable contraception~* life expectance \< 50 % at 1 year~* major surgery planned within 6 months~* participation in other clinical trials or impossibility to give written consent~* acute coronary syndrome or cardiogenic shock within the last 4 weeks~* stent thrombosis, defined as probable or definite by ARC~* contraindication against dual antiplatelet therapy~* allergy against mTOR-inhibitors or taxol derivates~* target lesion situated in the left main coronary artery, in a bypass graft or a grafted vessel~* reference luminal diameter of the target lesion \> 3.75 mm or \< 2.0 mm~* lesion length \> 30 mm, bifurcation lesion requiring intervention on a major side branch

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BRS (Type: ACTIVE_COMPARATOR): OCT-guided BRS implantation: implantation of a bioresorbable scaffold (BRS) under OCT guidance.~Note: Absorb™ from Abbott Vascular has been used as BRS until this product became unavailable in April 2017. Currently the recruitment is stopped due to this issue, until the use of another BRS gets final approval.
- DCB-only (Type: EXPERIMENTAL): FFR-guided DCB-only PCI: PCI using DCB (SeQuent Please™, B Braun Melsungen GmBH) without stent implantation und FFR guidance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Integrated Care of Co-morbidities vs Standard Care After AHRF in the Intensive Care Unit

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consent form signed~* Acute hypercapnic respiratory failure defined as PaCO2 \> 6.3 kPa requiring invasive or non-invasive mechanical ventilation in the ICU~Exclusion Criteria:~* Age \< 18 years old~* Known or suspected neuromuscular diseases~* Pregnancy~* Iatrogenic respiratory failure (i.e. drug overdose, AHRF after starting opiates or increasing opiates dose)~* Life expectancy \< 3 months~* Confusion or major psychiatric illness~* Patient unable to be weaned from NIV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Bundle of comorbidities care
- Control (Type: NO_INTERVENTION): Standard care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Visual Telerehabilitation in AMD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Dry-AMD.~* BCVA \> 20/160.~* Ability to follow the visual and auditory stimuli and training instructions.~* Auditory test positive at 50Hz 25-60dBHL.~* Home Wi-Fi access.~Exclusion Criteria:~* Wet AMD.~* Both eyes with media opacity that impairs microperimetry testing.~* Inability to perform during testing and training.~* Psychoactive drugs consumption.~* 3 consecutive VRISE scores \< 25 at inclusion.~* History of vertigo or dizziness~* Prior vision rehabilitation interventions.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Biofeedback Training (Type: ACTIVE_COMPARATOR): * Biofeedback training (BFT): 1 sessions of 4 x 20 minutes blocks. Rest time of 5 minutes between blocks. 1 session per week for 4 weeks (4 sessions total).~* 30 min daily reading at home for 4 weeks.
- Biofeedback Training + Immersive VR (Type: EXPERIMENTAL): * Biofeedback training (BFT) \[1 sessions of 4 x 20 minutes blocks. Rest time of 5 minutes between blocks\], 1 session per week for 4 weeks (4 sessions total).~* 30 min daily reading at home for 4 weeks~* Immersive virtual-reality stimulation (IVR) \[1 session of 3 blocks of 15 trials of 20 seconds each. Rest time is 1-2 minute(s) between blocks\], 1 session every 2 days for 4 weeks (14 sessions total).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Metronidazole Prophylaxis Against Clostridium Difficile-Associated Diarrhea in High Risk Adult Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inpatients \>55~* Proton Pump inhibitor / Histamine-2 Blocker~* On broad spectrum antibiotics (Zosyn and/or Ciprofloxacin). These two antibiotics are selected based on current hospital formulary/use~* Anticipated hospital stay \>48 hours~* Mental capacity (able to give informed written consent).~Exclusion Criteria:~* Admission for CDI~* Existing diarrhea at admission~* Passed prophylactic window (\>48 hours on broad spectrum antibiotics)~* Unable to take PO at the time of evaluation for study entry~* No more than 14 days of broad spectrum antibiotics anticipated~* Medications with serious interactions/contraindications to that would be taken together with metronidazole (ex. Warfarin, disulfiram, phenytoin, calcineurin inhibitors)~* Inflammatory Bowel Disease~* Admission for colonic bowel surgery or h/o total/Subtotal colectomy)~* Hospice~* Mortality expected \<7days~* Previous CDI in the past 6 months~* Intensive care admission due to the difficulty of monitoring them~* Allergy to Metronidazole or other Antibiotics in protocol~* Patients with neuropathy~* History of heavy ethyl alcohol intake(greater than 3 drinks daily) or intake in past 24 hours,Solid organ transplant.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metronidazole (Type: EXPERIMENTAL): Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Parenteral Nutrition-Associated Cholestasis With Cyclic Parenteral Nutrition in Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Infants expected to need prolonged PN (receiving \>75% PN on dol 7) with the following risk factors:~   1. Prematurity with gestational age (GA) \<32 weeks AND birth weight \<1500g. OR~  2. Congenital anomaly of the gastrointestinal tract regardless of GA or BW~2. Screening direct bilirubin prior to the initiation of parenteral nutrition \<2mg/dL.~Exclusion Criteria:~1. Infants with major congenital anomalies, other than those of the gastrointestinal tract.~2. Infants with known obstruction of the hepatobiliary tract.~3. Infants with suspected congenital infection or suspected genetic/metabolic syndrome predisposing them to cholestasis based on direct bilirubin \> 2mg/dL prior to instituting PN.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 7 Days
- Healthy Volunteers: f

Study Arms:
- Cycling Parenteral Nutrition (Type: EXPERIMENTAL): Infants in the intervention cycling group will receive infusion of carbohydrate/amino acids and intralipid over a 20-hour period. During the 4-hour window period, infants in this group will receive dextrose solution only at the same rate calculated for the carbohydrate/amino acid infusion.
- Continuous Parenteral Nutrition (Type: ACTIVE_COMPARATOR): Infants in this control group will receive infusion of carbohydrates/amino acids and intralipids continuously, over 24 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented tissue diagnosis of pancreatic ductal adenocarcinoma with a sufficient amount of tissue for Laser Capture Micro-dissection (LCM) of the stromal and tumour compartments.~* Confirmed eligibility for a Whipple's or distal pancreatectomy procedure by Multi-Disciplinary Team (MDT) and surgeon review.~* Adequate organ function defined as:~  * Creatinine clearance ≥ 50ml/min (as defined by Cockcroft-Gault)~ * Electrolytes (Sodium (Na)/Potassium (K)/Calcium (Ca)) within institutional normal limits~ * Alanine transaminase (ALT)/Aspartate transaminase (AST) \<5\*ULN~ * Partial thromboplastin time (PTT)\<2\*ULN, prior supplementation with vitamin K is allowed~ * Adequate blood counts: neutrophils \>1,500/μl, Hb \> 6mmol/L,platelets \>100.000/μl~ * Albumin ≥ 25mg/dL~* Written informed consent~* Male or female aged 18 years or over.~* World Health Organization (WHO) performance status 0-1~* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.~* Males should not donate sperm during treatment or up to 3 months after the last dose.~* Women of childbearing potential are required to have a negative serum pregnancy test (with sensitivity of at least 25 mIU/mL) within 10-14 days and within 24 hours prior to the first dose of GDC-0449.~Exclusion Criteria:~* Known Hepatitis B/C or Human Immunodeficiency Virus (HIV) infection~* Known hypersensitivity to GDC-0449~* Active cardiac ischemic disease (this criterion only applies for participation in the imaging part of the study)~* Women, who are pregnant plan to become pregnant or are lactating (during the study or for up to 12 months after the last dose).~* Concurrent participation in another clinical trial using an investigational medicinal product.~* Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or in the judgment of the investigator would make it undesirable for the patient to enter the trial (i.e. patients is not able to swallow tablets).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GDC-0449 (Type: EXPERIMENTAL): Study drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mesenchymal Stem Cells to Intervene in the Development of Type 1 Diabetes: a Blinded Randomized Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* fasting C-peptide \>0.12 nmol/l~* within three weeks of diagnosis of type 1 diabetes~Exclusion Criteria:~* body mass index (BMI) \>30~* unstable cardiovascular status incl. New York Heart Association (NYHA) class III/IV~* patients with known or previous malignancy~* active infections incl. serological evidence of infection with HIV, Treponema pallidum, hepatitis B (patients with serology consistent with previous vaccination and a history of vaccination are acceptable) or hepatitis C.~* immune suppressive treatment~* women being pregnant or nursing, or women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- sham transplantation of mesenchymal stem cells (Type: PLACEBO_COMPARATOR): control arm with sham transplantation
- autologous mesenchymal stem cell transplantation (Type: ACTIVE_COMPARATOR): Active arm with transplantation of cells

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Transfusion-Associated Microchimerism in Previously Injured Individuals Who Received a Blood Transfusion

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized for traumatic injury, thermal injury, or an elective orthopedic surgical procedure from 2000 to 2003 at the University of California at Davis Medical Center~* Received at least 1 unit of transfused red blood cells~Exclusion Criteria:~* Currently incarcerated~* Inadequate decision-making capacity of the participant and no available surrogate decision-maker~* Prior bone marrow or solid organ transplantation~* Prior blood transfusion other than at the time of hospitalization~* Any history of an autoimmune disorder prior to hospitalization

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Traumatic injury
- 2 (Type: None): Elective orthopedic surgery
- 3 (Type: None): Burn injury

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who signed an informed consent form~* Patients who underwent resection or biopsy for GBM~* KPS\> 70~Exclusion Criteria:~* Patients being treated with antidepressants~* Unable to answer the questionnaires because of an inability to communicate~* Patients being treated; monoamine oxidase inhibitors (MAOI) CYP1A2 Inhibitors or (CYP2D6 inhibitors (SSRIs such as fluoxetine, paroxetine, or anti-arrhythmia such as quinidine) Patients with Glaucoma, narrow angle~* Severe renal dysfunction. According to laboratory criteria specified earlier.~* Hepatic insufficiency - which laboratory criteria mentioned earlier.~* Pregnant women Patients Dementia~* Patients who previously suffered from depression in the past or within 5 years of diagnosis, and currently do not receive drug therapy~* Sensitivity to any of its ingredients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group # 1- ACTIVE (Type: ACTIVE_COMPARATOR): Patients who underwent resection or biopsy of glioblastoma (newly diagnosed glioblastoma), will randomization ratio of 1: 1 by the pharmacist (by age, KPS, the degree of tumor resection) two research groups:~Group # 1: consisting of 50 patients who will be treated immediately after diagnosis, 30 mg Cymbalta duloxetine -morning for a week and then a dose exceeding 60 mg for 3 months.
- Group # 2-PLACEBO (Type: PLACEBO_COMPARATOR): Group # 2 will include 50 patients treated immediately after diagnosis with placebo for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues